慢性淋巴细胞白血病治疗进展

Treatment progress of chronic lymphocytic leukemia

慢性淋巴细胞白血病(CLL)是一种高度异质性疾病,在传统免疫化疗时代,以利妥昔单抗+氟达拉滨+环磷酰胺(FCR)为代表的联合化疗方案取得了巨大成绩,但是对于遗传学高风险患者、复发难治患者以及不能耐受的老年患者,疗效不佳。以BTK抑制剂为代表的新药一定程度上解决了上述问题,有望迎来CLL治疗的无化疗时代,以期为停药带来可能。现就CLL治疗进展进行综述。

Chronic lymphocytic leukemia(CLL)is a highly heterogeneous disease,and combined chemotherapies symbolized by rituximab+fludarabine+cyclophosphamide have made great achievements in the era of traditional immunochemotherapy.However,for the patients with high genetic risk,relapsed and refractory patients as well as the elderly patients who cannot tolerate it,the therapeutic effect of this regimen is not good.The new drugs represented by BTK inhibitors have solved the above problems to a certain extent,and it is hopeful to move into the chemotherapy-free age of CLL treatment and bring the possibility of drug withdrawal.This article reviews the progress of CLL treatment.